Fong et al. have revealed that the inhibition of PRMT5 and type I protein arginine methyltransferases (PRMTs) by GSK3203591 and MS023, respectively, reduces splicing fidelity and results in the preferential killing of SF (splicing factor)-mutant leukemias over wild-type counterparts and that their combination exhibits synergistic effects in killing tumor cells55. Here, SLU7 is linked to neoplasm.